Investor Relations

Company Description

News

Financial Reports

Financial Calendar

Presentations

The Share

New Issues

Corporate Governance

IR Contact

Preliminary results of DigniCap Delta study demonstrate 79 percent efficacy

Dignitana announces that the Hospital de Clínicas in Montevideo, Uruguay has completed the first stage of a two-year investigational study of DigniCap efficacy in women with breast and ovarian cancer led by Dr. Gabriel Krygier, Director of the Department of Oncology at Hospital de Clínicas.

Dr. Krygier reports the first phase of the study demonstrated a 79 percent success rate, with 19 of the 24 patients using DigniCap Delta retaining more than 50 percent of their hair (65-95 percent). Additionally, two patients lost 50 percent of their hair and three patients discontinued treatment due to cold intolerance during the study.

The Breast Cancer Rapid Resolution Program study shows a direct improvement on the quality of life of cancer patients, Dr. Krygier explained, “It is not only the treatment, the surgery, the chemo, but being able to know that the treatment ends while preserving the hair, which implies dignity in the patient,” he explained. “DigniCap cooled the scalp and, thus, prevented between 65 percent and 95 percent of hair loss in patients with solid tumors receiving chemotherapy.”

In March 2022 Hospital de Clínicas was the first in Latin America to offer the DigniCap Delta Scalp Cooling System to minimize hair loss from chemotherapy, as highlighted by Dr. Krygier in this video. With increased interest and utilization, the hospital purchased a second DigniCap Delta device in October 2023.

The FDA-cleared DigniCap Scalp Cooling System minimizes hair loss from chemotherapy for cancer patients with solid tumors such as breast, prostate and gynecological cancers.

Uruguay has one of  the highest incidences of cancer in Latin America, with Breast cancer accounting for 25.4 percent of cancers in women and 12 percent of diagnoses among men and women, the second highest of all cancer types (Globocan 2020).

Recognized internationally as a standard of care and quality of life advancement for cancer patients, scalp cooling is listed as a treatment recommendation in the clinical practice guidelines published by European Society for Medical Oncology (ESMO), National Comprehensive Cancer Network® (NCCN) and Cancer Australia.

For More Information Contact 

Melissa Bourestom, Chief Communications Officer,  melissa.bourestom@dignitana.com  +1 469-518-5031

About Dignitana

Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001.  Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and US operations based in Dallas, Texas in the United States.  Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB. Learn more at www.dignitana.com or www.dignicap.com.